Press Releases

Phase III study met all co-primary and secondary endpoints and achieved statistically significant resultsWorld pharma today/-press releases/-Allergan Plc and Gedeon Richter Plc. announced positive results from Venus I, one of two pivotal Phase III clinical trials evaluating the efficacy...

With unprecedented levels of rail investment and the rise of national infrastructure up the political agenda, there was an upbeat mood at the Infrarail 2016 exhibition of railway infrastructure products and services and at CITE 2016, covering the civil...

SHANGHAI, April 21, 2016 /PRNewswire/ -- The Health Industry Summit (tHIS) 2016 opened in Shanghai at the National Exhibition and Convention Center on April 17. The organizer posted a record 380,000 entry scans, 216,784 professional visitors and...

AstraZeneca announced that it has completed the divestment of the global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $190...

AbbVie, a global biopharmaceutical company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion in favor of the use of IMBRUVICA® (ibrutinib) for the treatment of adult...

Biogen announced the appointment of Michael Ehlers, M.D., Ph.D., as executive vice president, Research and Development. World pharma today/Press releases /-Dr. Ehlers will oversee Biogen’s global Research, Drug Discovery, Clinical Development, and Medical Affairs functions, defining...

The GOLDEN-3 and GOLDEN-4 Phase 3 trials evaluating SUN-101/eFlow® in people with moderate-to-very severe COPD met their primary endpoint with a statistically significant change from baseline in trough FEV1 at Week 12. World pharma today/Press releases...